News
PATH & MMV set date for eliminating relapsing malaria
Medicines for Malaria Venture (MMV) and healthcare non-profit PATH have launched a five-year initiative to support countries in elimination of Plasmodium vivax (P. vivax)...
Pfizer & Lilly report top-line results for tanezumab
Pfizer and Eli Lilly have reported top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
The objective of the study...
In brief: Ipsen closes Clementia acquisition
Ipsen has closed its acquisition of Canada’s Clementia Pharmaceuticals after securing approval from shareholders and the Quebec Superior Court.
Clementia shareholders will receive $25.00 per...
